Cohort profile: early pandemic evaluation and enhanced surveillance of COVID-19 (EAVE II) database

Rachel H Mulholland; Eleftheria Vasileiou; Colin R Simpson; Chris Robertson; Lewis D. Ritchie; Utkarsh Agrawal; Mark Woolhouse; Josephine LK Murray; Helen R Stagg; Annemarie B Docherty; Colin McCowan; Rachael Wood; Sarah J Stock; Aziz Sheikh

doi:10.1093/ije/dyab028

Cohort profile: early pandemic evaluation and enhanced surveillance of COVID-19 (EAVE II) database

Rachel H Mulholland, Eleftheria Vasileiou, Colin R Simpson, Chris Robertson, Lewis D. Ritchie, Utkarsh Agrawal, Mark Woolhouse, Josephine LK Murray, Helen R Stagg, Annemarie B Docherty, Colin McCowan, Rachael Wood, Sarah J Stock, Aziz Sheikh

Mathematics And Statistics

Research output: Contribution to journal › Article › peer-review

34 Citations (Scopus)

45 Downloads (Pure)

Abstract

In December 2019, a novel coronavirus COVID-19 emerged from Wuhan, China, and was soon declared as pandemic by the World Health Organization (WHO) on the 11 March 2020.1 The UK soon followed suit and implemented a national lockdown on the 23 March 2020. As of 9 December 2020, according to WHO, this highly infectious virus has infected more than 67 million people and led to over 1.5 million deaths across the world.2 There is a growing body of evidence on the epidemiology of the condition, risk factors for poor outcomes and effects of interventions.3–9

The rapid generation of robust data is crucial to monitor, understand and mitigate the effects of COVID-19. The Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) database creates a national, real-time prospective cohort using Scotland’s health data infrastructure, to describe the epidemiology of COVID-19 infection, patterns of healthcare use and outcomes, and insights into the effectiveness of and safety of vaccines and treatments for COVID-19.10

This work builds on an established cohort for seasonal and pandemic influenza vaccine and anti-viral assessment in Scotland EAVE (Early Estimation of Vaccine and Anti-Viral Effectiveness).11,12 EAVE is a dormant pandemic protocol that is part of the National Institute for Health Research (NIHR) Pandemic Preparedness Research Portfolio and a platform for previous studies on influenza vaccine and antiviral assessment.

Original language	English
Pages (from-to)	1064-1074
Number of pages	11
Journal	International Journal of Epidemiology
Volume	50
Issue number	4
Early online date	5 Jun 2021
DOIs	https://doi.org/10.1093/ije/dyab028
Publication status	Published - 30 Aug 2021

Keywords

general medicine
epidemiology
Covid 19

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/ije/dyab028

Mulholland-etal-IJE-2021-Cohort-profile-early-pandemic-evaluation-and-enhanced-surveillanceAccepted author manuscript, 1.26 MB

https://www.research.ed.ac.uk/en/publications/cohort-profile-early-pandemic-evaluation-and-enhanced-surveillanc

Cite this

Mulholland, R. H., Vasileiou, E., Simpson, C. R., Robertson, C., Ritchie, L. D., Agrawal, U., Woolhouse, M., Murray, J. LK., Stagg, H. R., Docherty, A. B., McCowan, C., Wood, R., Stock, S. J., & Sheikh, A. (2021). Cohort profile: early pandemic evaluation and enhanced surveillance of COVID-19 (EAVE II) database. International Journal of Epidemiology, 50(4), 1064-1074. https://doi.org/10.1093/ije/dyab028

@article{933f14b34631498887246d15f8acc8c3,

title = "Cohort profile: early pandemic evaluation and enhanced surveillance of COVID-19 (EAVE II) database",

abstract = "In December 2019, a novel coronavirus COVID-19 emerged from Wuhan, China, and was soon declared as pandemic by the World Health Organization (WHO) on the 11 March 2020.1 The UK soon followed suit and implemented a national lockdown on the 23 March 2020. As of 9 December 2020, according to WHO, this highly infectious virus has infected more than 67 million people and led to over 1.5 million deaths across the world.2 There is a growing body of evidence on the epidemiology of the condition, risk factors for poor outcomes and effects of interventions.3–9The rapid generation of robust data is crucial to monitor, understand and mitigate the effects of COVID-19. The Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) database creates a national, real-time prospective cohort using Scotland{\textquoteright}s health data infrastructure, to describe the epidemiology of COVID-19 infection, patterns of healthcare use and outcomes, and insights into the effectiveness of and safety of vaccines and treatments for COVID-19.10This work builds on an established cohort for seasonal and pandemic influenza vaccine and anti-viral assessment in Scotland EAVE (Early Estimation of Vaccine and Anti-Viral Effectiveness).11,12 EAVE is a dormant pandemic protocol that is part of the National Institute for Health Research (NIHR) Pandemic Preparedness Research Portfolio and a platform for previous studies on influenza vaccine and antiviral assessment.",

keywords = "general medicine, epidemiology, Covid 19",

author = "Mulholland, {Rachel H} and Eleftheria Vasileiou and Simpson, {Colin R} and Chris Robertson and Ritchie, {Lewis D.} and Utkarsh Agrawal and Mark Woolhouse and Murray, {Josephine LK} and Stagg, {Helen R} and Docherty, {Annemarie B} and Colin McCowan and Rachael Wood and Stock, {Sarah J} and Aziz Sheikh",

year = "2021",

month = aug,

day = "30",

doi = "10.1093/ije/dyab028",

language = "English",

volume = "50",

pages = "1064--1074",

journal = "International Journal of Epidemiology",

issn = "0300-5771",

publisher = "Oxford University Press",

number = "4",

}

Mulholland, RH, Vasileiou, E, Simpson, CR, Robertson, C, Ritchie, LD, Agrawal, U, Woolhouse, M, Murray, JLK, Stagg, HR, Docherty, AB, McCowan, C, Wood, R, Stock, SJ & Sheikh, A 2021, 'Cohort profile: early pandemic evaluation and enhanced surveillance of COVID-19 (EAVE II) database', International Journal of Epidemiology, vol. 50, no. 4, pp. 1064-1074. https://doi.org/10.1093/ije/dyab028

TY - JOUR

T1 - Cohort profile

T2 - early pandemic evaluation and enhanced surveillance of COVID-19 (EAVE II) database

AU - Mulholland, Rachel H

AU - Vasileiou, Eleftheria

AU - Simpson, Colin R

AU - Robertson, Chris

AU - Ritchie, Lewis D.

AU - Agrawal, Utkarsh

AU - Woolhouse, Mark

AU - Murray, Josephine LK

AU - Stagg, Helen R

AU - Docherty, Annemarie B

AU - McCowan, Colin

AU - Wood, Rachael

AU - Stock, Sarah J

AU - Sheikh, Aziz

PY - 2021/8/30

Y1 - 2021/8/30

N2 - In December 2019, a novel coronavirus COVID-19 emerged from Wuhan, China, and was soon declared as pandemic by the World Health Organization (WHO) on the 11 March 2020.1 The UK soon followed suit and implemented a national lockdown on the 23 March 2020. As of 9 December 2020, according to WHO, this highly infectious virus has infected more than 67 million people and led to over 1.5 million deaths across the world.2 There is a growing body of evidence on the epidemiology of the condition, risk factors for poor outcomes and effects of interventions.3–9The rapid generation of robust data is crucial to monitor, understand and mitigate the effects of COVID-19. The Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) database creates a national, real-time prospective cohort using Scotland’s health data infrastructure, to describe the epidemiology of COVID-19 infection, patterns of healthcare use and outcomes, and insights into the effectiveness of and safety of vaccines and treatments for COVID-19.10This work builds on an established cohort for seasonal and pandemic influenza vaccine and anti-viral assessment in Scotland EAVE (Early Estimation of Vaccine and Anti-Viral Effectiveness).11,12 EAVE is a dormant pandemic protocol that is part of the National Institute for Health Research (NIHR) Pandemic Preparedness Research Portfolio and a platform for previous studies on influenza vaccine and antiviral assessment.

AB - In December 2019, a novel coronavirus COVID-19 emerged from Wuhan, China, and was soon declared as pandemic by the World Health Organization (WHO) on the 11 March 2020.1 The UK soon followed suit and implemented a national lockdown on the 23 March 2020. As of 9 December 2020, according to WHO, this highly infectious virus has infected more than 67 million people and led to over 1.5 million deaths across the world.2 There is a growing body of evidence on the epidemiology of the condition, risk factors for poor outcomes and effects of interventions.3–9The rapid generation of robust data is crucial to monitor, understand and mitigate the effects of COVID-19. The Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) database creates a national, real-time prospective cohort using Scotland’s health data infrastructure, to describe the epidemiology of COVID-19 infection, patterns of healthcare use and outcomes, and insights into the effectiveness of and safety of vaccines and treatments for COVID-19.10This work builds on an established cohort for seasonal and pandemic influenza vaccine and anti-viral assessment in Scotland EAVE (Early Estimation of Vaccine and Anti-Viral Effectiveness).11,12 EAVE is a dormant pandemic protocol that is part of the National Institute for Health Research (NIHR) Pandemic Preparedness Research Portfolio and a platform for previous studies on influenza vaccine and antiviral assessment.

KW - general medicine

KW - epidemiology

KW - Covid 19

U2 - 10.1093/ije/dyab028

DO - 10.1093/ije/dyab028

M3 - Article

SN - 0300-5771

VL - 50

SP - 1064

EP - 1074

JO - International Journal of Epidemiology

JF - International Journal of Epidemiology

IS - 4

ER -

Cohort profile: early pandemic evaluation and enhanced surveillance of COVID-19 (EAVE II) database

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this